A Primer on Brexanolone (Zulresso) for Postpartum Depression
Since the the Food and Drug Administration (FDA) approved brexanolone as an intravenous infusion for the treatment of postpartum depression last week, we have been deluged with questions from patents, providers and the media regarding this new drug. Sage Therapeutics plans to market the drug under the name